I'm Having Vaginal Dryness, Burning, or Pain With Sex Since Menopause — Can Creams Actually Fix This, or Do I Just Have to Live With It?
Quick Answer
No, you don't have to live with it, and yes, it's treatable, but only if the treatment actually touches the tissue. This has a name, genitourinary syndrome of menopause, or GSM, and it happens because the vulva, vagina, and lower urinary tract are estrogen-dependent tissue that thins and changes once estrogen drops. Oral, patch, and pellet hormone therapy don't reliably fix it. Estradiol or testosterone cream applied directly to the vulvar and vaginal tissue does.
What GSM Actually Is
Vaginal dryness, burning, irritation, and pain with sex after menopause have a name: genitourinary syndrome of menopause, or GSM. It happens because the tissue of the vulva, vagina, and lower urinary tract is estrogen-dependent, and once estrogen drops at menopause, that tissue thins, loses elasticity, and stops producing adequate lubrication on its own. It's not something you have to accept as a permanent part of aging. It's a tissue problem, and tissue problems respond to direct treatment.
GSM doesn't stop at dryness and discomfort during sex. Estrogen also maintains vaginal pH and the healthy lactobacilli population that keeps that environment acidic and resistant to pathogens. When estrogen drops, vaginal pH rises, lactobacilli decline, and the local microflora shifts toward organisms that don't belong there. That's a big part of why postmenopausal women see a rise in recurrent UTIs. It's not a coincidence or just getting older, it's a direct consequence of the same tissue and pH changes driving GSM. The same estrogen-dependent thinning affects the urethra and the tissue supporting it, which contributes to urgency, incontinence, and pelvic floor dysfunction as well. GSM is really a urinary problem as much as a vaginal one, and treating it can improve UTI frequency and bladder symptoms alongside the sexual and comfort symptoms most women come in asking about.
Why Your Current Hormone Therapy May Not Be Covering This
If you're on oral estrogen, a patch, or a pellet for hot flashes, mood, or bone protection, you'd reasonably assume that's also treating GSM. Often it isn't, or not fully. Systemic estradiol raises estrogen in your bloodstream, but blood levels don't reliably translate into the concentration of estrogen the vulvar and vaginal tissue, and the urethra along with it, actually needs to rebuild. That tissue needs direct contact.
That's why local treatment applied straight to the vaginal and vulvar tissue works differently, and for GSM specifically, works better than anything delivered systemically. There are two options I use, and they don't do the same thing.
Vaginal Estradiol: A Local Fix, and Only a Local Fix
Vaginal estradiol cream applied directly to the tissue restores the vaginal lining, normalizes pH, and reestablishes a healthy lactobacilli-dominant microflora, which is a large part of why it reduces recurrent UTIs in postmenopausal women. It corrects dryness and thinning and improves comfort and function locally. What it does not do is meaningfully raise your blood estradiol level. The absorption into circulation is low by design, which is part of why it's considered safe for women who otherwise couldn't take systemic estrogen. But that also means vaginal estradiol is a local fix only. It won't touch hot flashes, and it won't contribute to the whole-body benefits systemic estrogen provides, things like bone density protection, cardiovascular effects, and the neuroprotective effects associated with estrogen's role in the brain.
Testosterone Cream: Local Rejuvenation Plus a Systemic Contribution
Testosterone cream applied to the same tissue does something additional. The vulvar and vaginal tissue contains the enzymatic machinery, aromatase and 5-alpha reductase, needed to convert testosterone into estradiol and DHT locally. So when testosterone cream is applied there, some of it converts to estradiol right in the tissue, producing the same local rejuvenation effect as estradiol cream, including the pH and microflora restoration.
At the same time, this tissue is thin, mucosal, and highly vascular, which makes it one of the most absorbant sites on the body for topical hormone delivery, far more absorbant than skin elsewhere. In my practice, tracking blood levels in patients using labial and vaginal testosterone cream, I see systemic testosterone levels comparable to what injectable or subcutaneous testosterone produces. That means this delivery method gives you both effects at once: the local tissue rejuvenation and the same systemic testosterone benefits, energy, libido, muscle maintenance, mood, you'd get from injections.
The practical takeaway: if GSM is your only concern and you don't need or want any systemic effect, vaginal estradiol cream applied directly is a well-supported, targeted option. If you're already a candidate for testosterone therapy, or you'd benefit from both the local tissue effect and a contribution to systemic testosterone, applying testosterone cream directly to the vulvar and vaginal tissue accomplishes both at once. Either way, the treatment has to physically touch the tissue. Oral pills, patches, and pellets don't deliver enough hormone to that specific location to fix GSM, the recurrent UTIs, or the incontinence on their own.
If you're dealing with these symptoms, don't assume your current hormone therapy already covers it. If you'd like an in-clinic consultation, here are all of the practices I see patients in. Prefer to start with a question first? Reach out directly by email or Instagram.
View My Clinic LocationsOr email drwilcox@precisionhormoneconsulting.com · DM @wellnessdoc_4everyoung on Instagram
— Dr. Darrell Wilcox · @wellnessdoc_4everyoung on Instagram
References
- Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. J Sex Med. 2014;11(12):2865–2872. PMID: 25155380.
- Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753–756. PMID: 8350884. (Randomized, double-blind, placebo-controlled trial; found intravaginal estriol lowered vaginal pH, restored lactobacilli-dominant flora, and reduced recurrent UTI incidence.)
- Rahn DD, Carberry C, Sanses TV, et al; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147–1156. PMID: 25415166.
- Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):343–350. PMID: 31794498. (Pooled review of systemic estradiol levels across low- and ultralow-dose vaginal estrogen products, using LC/MS or GC/MS assays; systemic absorption remained low across all doses studied.)
- Berman JR, Almeida FG, Jolin J, Raz S, Chaudhuri G, Gonzalez-Cadavid NF. Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status. Fertil Steril. 2003;79(4):925–931. PMID: 12749432. (First study to confirm aromatase and 5-alpha reductase type 1 and 2 mRNA expression in human vaginal tissue; establishes the enzymatic basis for local testosterone-to-estradiol and testosterone-to-DHT conversion referenced in this entry, not a measurement of systemic absorption.)
- "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. PMID: 35797481. (Cited for the whole-body effects of systemic estrogen referenced in this entry, bone loss and fracture prevention, and cardiovascular and cognitive risk considerations that differ by age and time since menopause.)
This content is for educational purposes only and does not constitute medical advice. The use of testosterone cream applied vaginally or vulvarly for genitourinary syndrome of menopause is not FDA-approved for this indication. Individual clinical decisions require physician evaluation and are made on a case-by-case basis. Dr. Wilcox is licensed to practice in multiple states. See About for current licensure.